BlueCrest Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

BlueCrest Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,051	Closed	-$235K	–	831
2018 Q3	$235K	Buy	+3,051	New	+$245K	0.01%	1184
2017 Q4	–	Sell	-7,498	Closed	-$500K	–	809
2017 Q3	$500K	Buy	+7,498	New	+$450K	0.02%	519
2017 Q2	–	Sell	-5,379	Closed	-$314K	–	890
2017 Q1	$314K	Buy	+5,379	New	+$258K	0.01%	514
2016 Q1	–	Sell	-9,376	Closed	-$609K	–	757
2015 Q4	$609K	Buy	9,376 +5,105	+120%	+$335K	0.03%	523
2015 Q3	$301K	Sell	4,271 -2,172	-34%	-$212K	0.01%	702
2015 Q2	$716K	Buy	+6,443	New	+$694K	0.02%	556

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BlueCrest Capital Management's AGIO Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2018, closing a stake of 3,051 shares — an estimated $235K sold.

BlueCrest Capital Management first reported a position in AGIO in Q2 2015 and held it in 6 quarters. The position peaked at $716K in Q2 2015. 196 funds tracked by Wall St. Rank hold AGIO as of Q4 2018.

BlueCrest Capital Management reported no remaining Agios Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 3,051 Agios Pharmaceuticals shares in Q4 2018, an estimated $235K.
BlueCrest Capital Management first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 6 quarters.
BlueCrest Capital Management's Agios Pharmaceuticals position peaked at $716K in Q2 2015.
196 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.